TransCode Therapeutics Announces Preliminary Clinical Results In First Patient In Phase 0 Clinical Study With Lead Therapeutic Candidate, TTX-MC138
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced preliminary results from its Phase 0 clinical trial of its lead therapeutic candidate, TTX-MC138, for treating metastatic cancer. The data showed that TTX-MC138 was successfully delivered to metastatic lesions and had pharmacokinetic behavior consistent with non-clinical IND-enabling studies. The patient tolerated the dosing with no reported adverse reactions. The trial is not intended to demonstrate a therapeutic effect but to inform dose selection and frequency for further clinical development.
October 24, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TransCode's preliminary results from its Phase 0 clinical trial of TTX-MC138 show successful delivery to metastatic lesions and tolerable dosing. This could potentially lead to further clinical development of the drug.
The successful delivery of TTX-MC138 to metastatic lesions and the tolerable dosing reported in the preliminary results of the Phase 0 clinical trial could potentially lead to further clinical development of the drug. This could have a positive impact on TransCode's stock in the short term as it indicates progress in the company's research and development efforts.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100